Adjudication of serious heart failure in patients from PROactive
Open accessThe DOI matches its Crossref record; 6 of the 6 references it cites were found in a registry or an index.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“In addition, TZDs increase the risk of HF, with the incremental risk of HF with pioglitazone at an estimated 0.4% annualized, absolute increase.170”
From 2023 ESC guidelines for the management of cardiovascular disease in patients with diabetes. (2023) · cites this paper as [170]
Citations
Cites
Dormandy, J. A., Charbonnel, B., Eckland, D. J., Erdmann, E., Massi-Benedetti, M., Moules, I. K., Skene, A. M., Tan, M. H., Lefèbvre, P. J., Murray, G. D., et al. (2005) · The Lancet · doi:10.1016/s0140-6736(05)67528-9 · Cited by 4,129
Guidelines for the diagnosis and treatment of chronic heart failure: executive summary (update 2005)
Swedberg, K., Cleland, J., Dargie, H., Drexler, H., Follath, F., Komajda, M., Tavazzi, L., Smiseth, O. A., Gavazzi, A., Haverich, A., et al. (2005) · European Heart Journal · doi:10.1093/eurheartj/ehi204 · Cited by 2,260
Self-citationThe PROactive study: some answers, many questions
Yki‐Järvinen, H. (2005) · The Lancet · doi:10.1016/s0140-6736(05)67504-6 · Cited by 148
Holman, R. R., Retnakaran, R. R., Farmer, A. A., & Stevens, R. (2006) · The Lancet · doi:10.1016/s0140-6736(06)67914-2 · Cited by 30
Holman, R. R., Retnakaran, R. R., Farmer, A. W., & Stevens, R. H. (2006) · The Lancet · Cited by 28
Guillausseau, P.-J. (2006) · The Lancet · doi:10.1016/s0140-6736(06)67911-7 · Cited by 8
Cited by
2023 ESC guidelines for the management of cardiovascular disease in patients with diabetes.
Marx, N., Federici, M., Schütt, K., Müller-Wieland, D., Ajjan, R. A., Antunes, M. J., Christodorescu, R. M., Crawford, C., Di Angelantonio, E., Eliasson, B., et al. (2023) · European Heart Journal · doi:10.1093/eurheartj/ehad192 · Cited by 1,642
Self-citationCardiac fibroblasts: At the heart of myocardial remodeling
Porter, K. E., & Turner, N. A. (2009) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2009.05.002 · Cited by 1,010
Lago, R. M., Singh, P. P., & Nesto, R. W. (2007) · The Lancet · doi:10.1016/s0140-6736(07)61514-1 · Cited by 710
Heart failure: a cardiovascular outcome in diabetes that can no longer be ignored
McMurray, J. J. V., Gerstein, H. C., Holman, R. R., & Pfeffer, M. A. (2014) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(14)70031-2 · Cited by 304
Erdmann, E., Charbonnel, B., Wilcox, R. G., Skene, A. M., Massi-Benedetti, M., Yates, J., Tan, M., Spanheimer, R., Standl, E., Dormandy, J. A., et al. (2007) · Diabetes Care · doi:10.2337/dc07-0717 · Cited by 290
Metadata
- Authors
- Rydén, L., Thráinsdóttir, I., & Swedberg, K.
- Affiliations
- Karolinska University Hospital (SE)
- Corresponding author
- Rydén, Lars
- Venue
- The Lancet
- Publisher
- Elsevier BV
- Published
- 2007-01
- Volume
- 369
- Issue
- 9557
- Pages
- 189-190
- ISSN
- 0099-5355 (ISSN-L)
- 0140-6736
- OpenAlex
- W2083719627
- Cited by
- 41
- References
- 6
- Citations by year
- 2026: 2 · 2025: 1 · 2024: 1 · 2023: 1 · 2021: 1 · 2020: 1 · 2018: 4 · 2017: 1 · 2016: 2 · 2015: 2 · 2014: 2 · 2012: 1
- FWCI
- 5.13
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Licence
- www.elsevier.com/tdm/userlicense/1.0/ (tdm)
- www.elsevier.com/legal/tdmrep-license (tdm)
- Locations
- The Lancet (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Heart Failure Treatment and Management
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Cardiovascular Function and Risk Factors
- Keywords
- heart failure, pioglitazone, PROactive trial, adjudication, type 2 diabetes, adverse events, peripheral edema, weight gain, macrovascular complications, SGLT2 inhibitors
- MeSH terms
- Pioglitazone, Heart Failure, Hospitalization, Humans, Hypoglycemic Agents, Pneumonia, Hospital Mortality, Thiazolidinediones
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Adjudication of serious heart failure in patients from PROactive. https://app.cochat.ai/papers/10.1016/s0140-6736(07)60106-8
- The paper
- Rydén, L., Thráinsdóttir, I., & Swedberg, K. (2007). Adjudication of serious heart failure in patients from PROactive. The Lancet. https://doi.org/10.1016/s0140-6736(07)60106-8
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.